SEARCH:   Advanced

Blood, 1 September 2005, Vol. 106, No. 5, pp. 1864-1866. Prepublished online as a Blood First Edition Paper on May 10, 2005; DOI 10.1182/blood-2005-03-1159. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-03-1159v1 106/5/1864    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kemna, E. Articles by Swinkels, D. Search for Related Content PubMed PubMed Citation Articles by Kemna, E. Articles by Swinkels, D. Related Collections Red Cells Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  RED CELLS Brief report Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS Erwin Kemna, Peter Pickkers, Elizabeta Nemeth, Hans van der Hoeven, and Dorine Swinkels From the Department of Clinical Chemistry, Radboud University Nijmegen Medical Centre, The Netherlands; Department of Intensive Care Medicine, Radboud University Nijmegen Medical Centre, The Netherlands; and Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA. Hepatic peptide hormone hepcidin is the key regulator of iron metabolism and the mediator of anemia of inflammation. Previous studies indicated that interleukin-6 (IL-6) mediates hepcidin increase and consequent hypoferremia during inflammation. Here we used an in vivo human endotoxemia model to analyze the effects of lipopolysaccharide (LPS) as a more upstream inflammation activator. The temporal associations between plasma cytokines, hepcidin levels, and serum iron parameters were studied in 10 healthy individuals after LPS injection. IL-6 was dramatically induced within 3 hours after injection, and urinary hepcidin peaked within 6 hours, followed by a significant decrease in serum iron. Serum prohepcidin showed no significant change within a 22-hour time frame. These in vivo human results confirm the importance of the IL-6-hepcidin axis in the development of hypoferremia in inflammation and highlight the rapid responsiveness of this iron regulatory system. (Blood. 2005;106: 1864-1866) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Kanda, C. Mizumoto, H. Kawabata, H. Tsuchida, N. Tomosugi, K. Matsuo, and T. Uchiyama Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation Haematologica, October 1, 2008; 93(10): 1550 - 1554. [Abstract] [Full Text] [PDF] L. Tacchini, E. Gammella, C. De Ponti, S. Recalcati, and G. Cairo Role of HIF-1 and NF-{kappa}B Transcription Factors in the Modulation of Transferrin Receptor by Inflammatory and Anti-inflammatory Signals J. Biol. Chem., July 25, 2008; 283(30): 20674 - 20686. [Abstract] [Full Text] [PDF] D. W. Swinkels and J. F. M. Wetzels Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol. Dial. Transplant., May 21, 2008; (2008) gfn267v1. [Full Text] [PDF] I. Theurl, M. Theurl, M. Seifert, S. Mair, M. Nairz, H. Rumpold, H. Zoller, R. Bellmann-Weiler, H. Niederegger, H. Talasz, et al. Autocrine formation of hepcidin induces iron retention in human monocytes Blood, February 15, 2008; 111(4): 2392 - 2399. [Abstract] [Full Text] [PDF] A. L. Lagan, D. D. Melley, T. W. Evans, and G. J. Quinlan Pathogenesis of the systemic inflammatory syndrome and acute lung injury: role of iron mobilization and decompartmentalization Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L161 - L174. [Abstract] [Full Text] [PDF] E. H.J.M. Kemna, H. Tjalsma, H. L. Willems, and D. W. Swinkels Hepcidin: from discovery to differential diagnosis Haematologica, January 1, 2008; 93(1): 90 - 97. [Abstract] [Full Text] [PDF] M. Bahador and A. S. Cross Review: From therapy to experimental model: a hundred years of endotoxin administration to human subjects Innate Immunity, October 1, 2007; 13(5): 251 - 279. [Abstract] [PDF] A. T. Murphy, D. R. Witcher, P. Luan, and V. J. Wroblewski Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry Blood, August 1, 2007; 110(3): 1048 - 1054. [Abstract] [Full Text] [PDF] H. Kawabata, N. Tomosugi, J. Kanda, Y. Tanaka, K. Yoshizaki, and T. Uchiyama Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease Haematologica, June 1, 2007; 92(6): 857 - 858. [Abstract] [Full Text] [PDF] E. H.J.M. Kemna, H. Tjalsma, V. N. Podust, and D. W. Swinkels Mass Spectrometry-Based Hepcidin Measurements in Serum and Urine: Analytical Aspects and Clinical Implications Clin. Chem., April 1, 2007; 53(4): 620 - 628. [Abstract] [Full Text] [PDF] T. Ganz Molecular Control of Iron Transport J. Am. Soc. Nephrol., February 1, 2007; 18(2): 394 - 400. [Abstract] [Full Text] [PDF] C. Benedict, A. J. Ghio, H. Gehring, B. Schultes, A. Peters, and K. M. Oltmanns Transient hypoxia and downregulation of circulating prohepcidin concentrations in healthy young men Haematologica, January 1, 2007; 92(1): 125 - 126. [Abstract] [Full Text] [PDF] H. Christiansen, N. Sheikh, B. Saile, F. Reuter, M. Rave-Frank, R. M. Hermann, J. Dudas, A. Hille, C. F. Hess, and G. Ramadori x-Irradiation in Rat Liver: Consequent Upregulation of Hepcidin and Downregulation of Hemojuvelin and Ferroportin-1 Gene Expression Radiology, December 1, 2006; 242(1): 189 - 197. [Abstract] [Full Text] [PDF] L. J. Wood, L. M. Nail, N. A. Perrin, C. R. Elsea, A. Fischer, and B. J. Druker The Cancer Chemotherapy Drug Etoposide (VP-16) Induces Proinflammatory Cytokine Production and Sickness Behavior-like Symptoms in a Mouse Model of Cancer Chemotherapy-Related Symptoms. Biol Res Nurs, October 1, 2006; 8(2): 157 - 169. [Abstract] [PDF] N. Sheikh, D. S. Batusic, J. Dudas, K. Tron, K. Neubauer, B. Saile, and G. Ramadori Hepcidin and hemojuvelin gene expression in rat liver damage: in vivo and in vitro studies Am J Physiol Gastrointest Liver Physiol, September 1, 2006; 291(3): G482 - G490. [Abstract] [Full Text] [PDF] K. B Hadley, L. K Johnson, and J. R Hunt Iron absorption by healthy women is not associated with either serum or urinary prohepcidin Am. J. Clinical Nutrition, July 1, 2006; 84(1): 150 - 155. [Abstract] [Full Text] [PDF] D. W. Swinkels, M. C.H. Janssen, J. Bergmans, and J. J.M. Marx Hereditary Hemochromatosis: Genetic Complexity and New Diagnostic Approaches Clin. Chem., June 1, 2006; 52(6): 950 - 968. [Abstract] [Full Text] [PDF] I. Theurl, V. Mattle, M. Seifert, M. Mariani, C. Marth, and G. Weiss Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease Blood, May 15, 2006; 107(10): 4142 - 4148. [Abstract] [Full Text] [PDF] T. Ganz Hepcidin and Its Role in Regulating Systemic Iron Metabolism Hematology, January 1, 2006; 2006(1): 29 - 35. [Abstract] [Full Text] [PDF] E. Kemna, H. Tjalsma, C. Laarakkers, E. Nemeth, H. Willems, and D. Swinkels Novel urine hepcidin assay by mass spectrometry Blood, November 1, 2005; 106(9): 3268 - 3270. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020